PMCB - PharmaCyte Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0545
+0.0057 (+11.68%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.0488
Open0.0494
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0457 - 0.0549
52 Week Range0.0300 - 0.0700
Volume6,679,412
Avg. Volume3,222,737
Market Cap75.857M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

    PharmaCyte Biotech successfully completes all release tests of its clinical trial product.

  • GlobeNewswire

    PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%

    This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double digits. While this is certainly good news, the increase in the 5-year survival rate was up just 1% to 10%, and there is still an unmet medical need for patients with locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte Biotech (PMCB) continues to move toward a planned Phase 2b clinical trial in LAPC to address those patients who no longer see any benefit after being treated for 4-6 months with one of two first-line therapies for the disease.

  • GlobeNewswire

    PharmaCyte Biotech Set to Reach Three Major Milestones in 2020

    PharmaCyte Biotech’s (PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones. This year the company’s therapy for locally advanced, inoperable pancreatic cancer (LAPC) should finally start to realize a number of key milestones that are both vital to the development of PharmaCyte’s leading product candidate and essential to the biotech investor. There are 3 milestones specifically that shareholders should be mindful of that could generate the kind of price appreciation that biotech investors have come to enjoy in both big and small bio/pharma companies with each of these same expected milestone announcements.

  • Business Wire

    PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product

    PharmaCyte Biotech passing all completed release testing of its clinical trial product for pancreatic cancer.

  • Business Wire

    PharmaCyte Biotech Provides Details on Quarterly Shareholder Update

    PharmaCyte Biotech postpones December 20, 2019 shareholder update to focus on completion of 10-Q and IND.

  • GlobeNewswire

    PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial

    PharmaCyte Biotech (PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator, and the company is ready to present its treatment for locally advanced, inoperable pancreatic cancer (LAPC) to the U.S. FDA in an effort to secure approval to begin a Phase 2b clinical trial in LAPC. LAPC is a hard-to-treat disease that leaves patients with very little hope after first-line therapies, Abraxane plus gemcitabine or FOLFIRINOX, no longer offer any benefit to this patient population.

  • Business Wire

    PharmaCyte Biotech to Hold Quarterly Shareholder Update

    PharmaCyte Biotech to hold shareholder update call on December 20, 2019. Questions to be submitted to PharmaCyte by December 13, 2019.

  • TEST Business Wire Releases

    PharmaCyte Biotech "Release Testing" Successful on All Completed Tests of Clinical Trial Product

    PharmaCyte Biotech announces that "release testing" has been successful on all completed tests thus far of its clinical trial material.

  • Business Wire

    PharmaCyte Biotech “Release Testing” Successful on All Completed Tests of Clinical Trial Product

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today an update on the completed tests that are part of the U.S. Food and Drug Administration (FDA) required “release testing” related to the company's first manufactured batch of its clinical trial product to be used in its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

  • Business Wire

    PharmaCyte Biotech Successfully Completes Final Manufacturing Run of Clinical Trial Product

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.” The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration (FDA) to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC).

  • GlobeNewswire

    PharmaCyte Biotech’s “Release Testing” Last Critical Event Before Submission of Investigational New Drug Application

    PharmaCyte Biotech (PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can submit an Investigational New Drug application (IND) to the U.S. FDA. PharmaCyte’s IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). With the FDA’s approval to begin a clinical trial, PharmaCyte’s opportunities for funding improve dramatically.

  • Business Wire

    PharmaCyte Biotech Closer to Submitting IND by Successfully Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, is closer to submitting an Investigational New Drug application (IND) to the U.S. Food & Drug Administration (FDA). PharmaCyte announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed encapsulation of the cells from PharmaCyte’s Master Cell Bank (MCB) in the second of two staggered and back-to-back manufacturing runs for the production of PharmaCyte’s clinical trial product.

  • GlobeNewswire

    PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

    Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.  First, successfully shrinking tumors would address a real unmet medical need for a group of patients that no longer realizes any benefit from either of the two first-line therapies.  Second, and of equal importance for the small California-based biotech, will be to utilize the company’s first-ever clinical trial to validate or prove that its signature live-cell encapsulation technology, Cell-in-a-Box®, is both effective and safe to use in humans. When asked about the importance of validating its technology in a clinical trial setting in relation to the company’s future, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “PharmaCyte is on the precipice of completely changing the paradigm for how diseases are treated in the future.

  • GlobeNewswire

    PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product

    NEW YORK, NY, Oct. 16, 2019 -- PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and.

  • Business Wire

    PharmaCyte Biotech Successfully Completes Manufacturing of Clinical Trial Product

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has completed the first of two staggered and back to back manufacturing runs for the production of PharmaCyte’s clinical trial product. The first manufacturing run has been completed successfully.

  • GlobeNewswire

    PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run

    During a conference call with shareholders late last week, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, told shareholders that the company is in the final days of the first of two back-to-back, staggered manufacturing runs, and that he is “very encouraged” by the reports he’s getting from Austrianova—the company conducting the manufacturing runs to produce the Cell-in-a-Box® capsules for PharmaCyte’s upcoming clinical trial. Once this first manufacturing run is completed successfully, the final stage in the process—testing those capsules and the live cells inside that make up the Cell-in-a-Box® technology—can begin.  The capsules will be placed into syringes and then those syringes will be frozen and stored in a freezer at Austrianova’s manufacturing facility in Thailand.  Soon thereafter, a representative sample of the Cell-in-a-Box® syringes will be thawed and a series of tests (release testing) will begin.  These FDA-required tests are necessary for PharmaCyte to be able to use its product in human beings in a clinical trial.